Laurus Labs Limited (LAURUSLABS)
Please see attached enclosure.
Investor Presentation - September 2026
- FY26 revenue ₹6,813 Cr +23% CAGR FY20-26 16%; EBITDA ₹1,826 Cr +64%, margin 26.8%
- 1QFY27 revenue ₹2,026 Cr +29% y-y; EBITDA ₹644 Cr +66%, margin 31.8%
- CDMO revenue growth driven by commercial projects; Affordable Medicines steady
- Capex accelerated: >₹3,000 Cr planned over FY27-FY28; 19% of 1QFY27 revenue
- Gene & ADC platform commissioning mid-2027; fermentation plant online by end 2026
- SBTi targets: >50% renewable electricity by 2031; GHG reduction validated
- Net debt/EBITDA 1.3x; strong operational leverage and margin expansion
- R&D spend ₹118 Cr (5.8% revenue), up 74%, focused on Advanced Biologics
- Multiple manufacturing sites with global regulatory approvals; 15 sites, 6 R&D centers
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 LAURUSLABS — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add LAURUSLABS to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Laurus Labs Limited
Important.
The summary above is generated automatically from Laurus Labs Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.